In the last trading session, 1,323,640 shares of the Altimmune, Inc.(NASDAQ:ALT) were traded, and its beta was 1.87. Most recently the company’s share price was $22.93, and it changed around -$0.58 or -0.02% from the last close, which brings the market valuation of the company to $851.69 Million. ALT currently trades at a discount to its 52-week high of $35.1, offering almost -53.07% off that amount. The share price’s 52-week low was $1.6, which indicates that the current value has risen by an impressive 93.02% since then. We note from Altimmune, Inc.’s average daily trading volume that its 10-day average is 1.58 Million shares, with the 3-month average coming to 1.94 Million.
Altimmune, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.7. If we narrow it down even further, the data shows that none out of 6 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended ALT as a Hold, whereas 6 deemed it a Buy, and no one rated it as Underweight. Altimmune, Inc. is expected to report earnings per share of -$0.75 for the current quarter.
Altimmune, Inc. (NASDAQ:ALT): Trading Information
Although ALT has showed a red trend with a performance of -2.47% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $24.61 on Thursday, Feb 18 increased the stock’s daily price by 6.83%. The company’s shares are currently up 1.03% year-to-date, but still up 0.0385 over the last five days. On the other hand, Altimmune, Inc. (NASDAQ:ALT) is 0.69% up in the 30-day period. We can see from the shorts that 2.61 Million shares have been sold at a short interest cover period of 1.35 day(s).
The consensus price target as assigned by Wall Street analysts is $42.67, which translates to bears needing to increase their stock price by 86.09% from its current value. Analyst projections state that ALT is forecast to be at a low of $24 and a high of $80. In order for the stock price to hit the forecast high, the stock would need to surge +248.89% from its current level, while the stock would need to crash 4.67% from its current level to reach the projected low.
Altimmune, Inc. (ALT) projections and forecasts
Altimmune, Inc. share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -6.14 percent over the past six months and at a -166.33% annual growth rate that is well below the industry average of 17.3%. However, despite this, analysts have decided to cut back on their fiscal year 2021 revenue estimates. The rating firms predict that it will lose -200% in revenue this quarter, and will report an increase of 30.8% in the next quarter. The year-over-year growth rate is expected to be 32.9%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $2.14 Million in revenue for the current quarter. 4 analysts expect Altimmune, Inc. to make $26.55 Million in revenue for the quarter ending March 01, 2021. The company’s sales for the same quarters a year ago were $575Million and $2.21 Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 272.2%. Forecasts for the next quarter put sales growth at 1099.7%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 50.2%. Altimmune, Inc. earnings are expected to increase by 89.5% in 2021, but the outlook is negative 0% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Altimmune, Inc. (NASDAQ:ALT)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 6.51% of Altimmune, Inc. shares, and 67.29% of them are in the hands of institutional investors. The stock currently has a share float of 71.98%. Altimmune, Inc. stock is held by 83 institutions, with VR Adviser, LLC being the largest institutional investor. By Sep 29, 2020, it held 13.61% of the shares, which is about 4.5 Million shares worth $59.4 Million.
Baker Brothers Advisors, LLC, with 6.67% or 2.21 Million shares worth $29.13 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.